HK1057377A1 - Suppressor gene - Google Patents

Suppressor gene

Info

Publication number
HK1057377A1
HK1057377A1 HK03108730A HK03108730A HK1057377A1 HK 1057377 A1 HK1057377 A1 HK 1057377A1 HK 03108730 A HK03108730 A HK 03108730A HK 03108730 A HK03108730 A HK 03108730A HK 1057377 A1 HK1057377 A1 HK 1057377A1
Authority
HK
Hong Kong
Prior art keywords
suppressor gene
modulating
activity
tumour suppressor
polypeptides capable
Prior art date
Application number
HK03108730A
Other languages
English (en)
Inventor
Xin Lu
Original Assignee
Ludwig Inst Cancer Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0019018A external-priority patent/GB0019018D0/en
Priority claimed from GB0029996A external-priority patent/GB0029996D0/en
Priority claimed from GB0112890A external-priority patent/GB0112890D0/en
Application filed by Ludwig Inst Cancer Res filed Critical Ludwig Inst Cancer Res
Publication of HK1057377A1 publication Critical patent/HK1057377A1/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4747Apoptosis related proteins
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/106Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/136Screening for pharmacological compounds
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00Screening for compounds of potential therapeutic value
    • G01N2500/02Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407Specifically defined cancers
    • G01N33/57415Specifically defined cancers of breast

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Steroid Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Audible-Bandwidth Dynamoelectric Transducers Other Than Pickups (AREA)
  • Bipolar Transistors (AREA)
HK03108730A 2000-08-04 2003-11-28 Suppressor gene HK1057377A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0019018A GB0019018D0 (en) 2000-08-04 2000-08-04 Suppressor gene
GB0029996A GB0029996D0 (en) 2000-12-08 2000-12-08 Suppressor gene
GB0112890A GB0112890D0 (en) 2001-05-26 2001-05-26 Suppressor Gene

Publications (1)

Publication Number Publication Date
HK1057377A1 true HK1057377A1 (en) 2004-04-02

Family

ID=27255828

Family Applications (1)

Application Number Title Priority Date Filing Date
HK03108730A HK1057377A1 (en) 2000-08-04 2003-11-28 Suppressor gene

Country Status (14)

Country Link
US (1) US20040053262A1 (zh)
EP (2) EP1710582A3 (zh)
JP (1) JP2004525605A (zh)
CN (1) CN1310942C (zh)
AT (1) ATE332309T1 (zh)
AU (2) AU2001276515B2 (zh)
CA (1) CA2417368A1 (zh)
CY (1) CY1106187T1 (zh)
DE (1) DE60121346T8 (zh)
DK (1) DK1313762T3 (zh)
ES (1) ES2269430T3 (zh)
HK (1) HK1057377A1 (zh)
PT (1) PT1313762E (zh)
WO (1) WO2002012325A2 (zh)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6852108B2 (en) 2002-05-14 2005-02-08 Spiration, Inc. Apparatus and method for resecting and removing selected body tissue from a site inside a patient
GB0223187D0 (en) * 2002-10-07 2002-11-13 Ludwig Inst Cancer Res Screen
CA2487206A1 (en) 2002-10-07 2004-04-15 Ludwig Institute Cancer Research P53 binding polypeptide
WO2005054509A2 (en) * 2003-12-04 2005-06-16 Ludwig Institute For Cancer Research Assay and treatment
WO2005054862A1 (en) * 2003-12-04 2005-06-16 Ludwig Institute For Cancer Research Screening assay and treatment
GB0328690D0 (en) * 2003-12-10 2004-01-14 Ludwig Inst Cancer Res Tumour suppressor protein
WO2005093098A1 (en) * 2004-03-12 2005-10-06 Ludwig Institute For Cancer Research Differential drug sensitivity
WO2008101133A2 (en) * 2007-02-14 2008-08-21 Cedars-Sinai Medical Center Methods of using genes and genetic variants to predict or diagnose inflammatory bowel disease
WO2008109782A2 (en) * 2007-03-06 2008-09-12 Cedars-Sinai Medical Center Diagnosis of inflammatory bowel disease in children
ATE477497T1 (de) * 2004-12-08 2010-08-15 Cedars Sinai Medical Center Verfahren zur diagnose von morbus crohn
US9051572B2 (en) 2005-01-20 2015-06-09 Ryboquin Company Limited Modulators of Itch ubiquitinase activity
WO2008045344A2 (en) * 2006-10-06 2008-04-17 The General Hospital Corporation Methods to determine responsiveness to cisplatin treatment
US20100190162A1 (en) * 2007-02-26 2010-07-29 Cedars-Sinai Medical Center Methods of using single nucleotide polymorphisms in the tl1a gene to predict or diagnose inflammatory bowel disease
WO2008137762A2 (en) * 2007-05-04 2008-11-13 Cedars-Sinai Medical Center Methods of diagnosis and treatment of crohn's disease
WO2008116150A2 (en) 2007-03-21 2008-09-25 Cedars-Sinai Medical Center Ileal pouch-anal anastomosis (ipaa) factors in the treatment of inflammatory bowel disease
US20100184050A1 (en) * 2007-04-26 2010-07-22 Cedars-Sinai Medical Center Diagnosis and treatment of inflammatory bowel disease in the puerto rican population
US20110177969A1 (en) * 2008-10-01 2011-07-21 Cedars-Sinai Medical Center The role of il17rd and the il23-1l17 pathway in crohn's disease
US20110229471A1 (en) 2008-11-26 2011-09-22 Cedars-Sinai Medical Center Methods of determining responsiveness to anti-tnf alpha therapy in inflammatory bowel disease
WO2010075579A2 (en) 2008-12-24 2010-07-01 Cedars-Sinai Medical Center Methods of predicting medically refractive ulcerative colitis (mr-uc) requiring colectomy
WO2011031884A2 (en) * 2009-09-10 2011-03-17 Mayo Foundation For Medical Education And Research Methods and materials for modulating deubiquitinases and ubiquitinated polypeptides
US9880171B2 (en) 2012-03-02 2018-01-30 Ludwig Institute For Cancer Research Ltd. iASPP phosphorylation and metastatic potential
CN112870368A (zh) 2013-03-27 2021-06-01 西达-赛奈医疗中心 通过抑制tl1a的功能和相关信号传导途径来减轻并逆转纤维化和炎症
EP3022295A4 (en) 2013-07-19 2017-03-01 Cedars-Sinai Medical Center Signature of tl1a (tnfsf15) signaling pathway
CN116426621A (zh) 2015-11-19 2023-07-14 赛纳生物科技(北京)有限公司 一种校正测序信息错误的方法
CN106874709B (zh) * 2015-12-12 2019-03-01 北京大学 测序结果中序列数据错误的检测和校正方法
EP3430172A4 (en) 2016-03-17 2019-08-21 Cedars-Sinai Medical Center METHOD FOR DIAGNOSIS OF INFLAMMATORY ENDURANCE THROUGH RNASET2

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5876950A (en) * 1995-01-26 1999-03-02 Bristol-Myers Squibb Company Monoclonal antibodies specific for different epitopes of human GP39 and methods for their use in diagnosis and therapy
US5977311A (en) * 1997-09-23 1999-11-02 Curagen Corporation 53BP2 complexes
AU6505599A (en) * 1998-10-05 2000-04-26 Ludwig Institute For Cancer Research Cancer associated antigens and uses therefor
US7141384B1 (en) * 1998-10-06 2006-11-28 Georgetown University Detection of pleiotrophin
WO2000032628A1 (fr) * 1998-12-03 2000-06-08 Ono Pharmaceutical Co., Ltd. INHIBITEUR DE LIAISON DE Re1A, PROCEDE DE PRODUCTION CORRESPONDANT ET UTILISATION DUDIT INHIBITEUR DE LIAISON
WO2001053312A1 (en) * 1999-12-23 2001-07-26 Hyseq, Inc. Novel nucleic acids and polypeptides
AU2001234944A1 (en) * 2000-02-03 2001-08-14 Hyseq, Inc. Novel nucleic acids and polypeptides

Also Published As

Publication number Publication date
US20040053262A1 (en) 2004-03-18
CN1446228A (zh) 2003-10-01
CA2417368A1 (en) 2002-02-14
ES2269430T3 (es) 2007-04-01
DK1313762T3 (da) 2006-10-30
CN1310942C (zh) 2007-04-18
DE60121346T8 (de) 2007-12-13
ATE332309T1 (de) 2006-07-15
EP1313762A2 (en) 2003-05-28
WO2002012325A3 (en) 2003-03-06
AU2001276515B2 (en) 2006-10-12
CY1106187T1 (el) 2011-06-08
PT1313762E (pt) 2006-11-30
DE60121346D1 (en) 2006-08-17
JP2004525605A (ja) 2004-08-26
AU7651501A (en) 2002-02-18
EP1710582A2 (en) 2006-10-11
DE60121346T2 (de) 2007-07-19
EP1313762B1 (en) 2006-07-05
EP1710582A3 (en) 2006-11-02
WO2002012325A2 (en) 2002-02-14

Similar Documents

Publication Publication Date Title
HK1057377A1 (en) Suppressor gene
DE69432031D1 (de) Huntingtin-DNA, Protein und Verwendung
ATE370232T1 (de) Anti-apo-2 antikörper
HUP0003533A2 (hu) Interleukin-18-at kötő fehérjék, előállításuk és alkalmazásuk
IL161016A (en) Polypeptides capable of ang-2 binding
DE69424209T2 (de) Tumorsuppressor-Gen Merlin und dessen Verwendungen
DE69735039D1 (de) Acetylhydrolase des Plättchen aktivierenden Faktors, und entsprechendes Gen
WO2000077179A3 (en) Human poly(adp-ribose) polymerase 2 materials and methods
ATE344802T1 (de) Angiogenese-assoziierte proteine und dafür kodierende nukleinsäure
WO2002018536A3 (fr) Proteine bard1 tronquee, et ses applications diagnostiques et therapeutiques
AU6679498A (en) A novel bak binding protein, dna encoding the protein, and methods of use thereof
WO1997026276A3 (en) Vertebrate fringe proteins
IL132632A0 (en) Dna encoding a gilr protein the protein its preparation and use
WO2003087832A3 (en) Diagnosis of carcinoma using raigi polypeptides
WO2002077190A3 (en) Isolated human ras-like proteins, nucleic acid molecules encoding these human ras-like proteins, and uses thereof
WO2001066745A3 (en) Presenilin/crk binding polypeptides (pcbp) and methods of use thereof
WO2002072765A3 (en) Isolated human ras-like proteins, nucleic acid molecules encoding these human ras-like proteins, and uses thereof
WO2002077220A3 (en) Nucleic acids encoding human est1 proteins
WO2002079494A3 (en) Isolated human ras-like proteins, nucleic acid molecules encoding these human ras-like proteins, and uses thereof
WO2002074976A3 (en) Isolated human ras-like proteins, nucleic acid molecules encoding these human ras-like proteins, and uses thereof
WO2002068468A3 (en) Isolated human tumor supressor proteins, nucleic acid molecules encoding these human tumor supressor proteins, and uses thereof
WO2002068648A3 (en) Isolated human ras-like proteins, nucleic acid molecules encoding these humans ras-like proteins, and uses thereof
WO2002077193A8 (en) Isolated human ras-like proteins, nucleic acid molecules encoding these human ras-like proteins, and uses thereof
WO2002074973A9 (en) Isolated human ras-like proteins, nucleic acid molecules encoding these human ras-like proteins, and uses thereof
WO2002061088A3 (en) Isolated human ras-like proteins, nucleic acid molecules encoding these human ras-like proteins, and uses thereof

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20100806